Clinical trials: Fulvestrant
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B)…
- Conditions
- Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
- Trial name
- NCT06784193
- Testing
- OP-3136, Fulvestrant, Palazestrant
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 180 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Breast Cancer, Fulvestrant
Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China
The purpose of this study is to evaluate efficacy and safety of CDK4/6 inhibitor Palbociclib in combination with Fulvestrant versus Fulvestrant in female patients with HR+/HER2- advanced breast cancer in a real world setting in…
- Conditions
- Breast Cancer, Fulvestrant, Palbociclib
- Trial name
- NCT04526028
- Testing
- Fulvestrant Injectable Product, Palbociclib
- Where
- China
- Volunteers
- 612 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Estrogen Receptor-positive Breast Cancer, Fulvestrant
The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer
This study is focused on the value of 18F-FES-PET in predicting the Fulvestrant efficacy in hormone receptor-positive breast cancer. The imaging agent involved in this study is 16α-[18F]-fluoro-17β-estradiol (18F-FES).
- Trial name
- PET (NCT03768479)
- Testing
- 18F-FES-PET
- Where
- China
- Volunteers
- 68 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University